Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -32.15% is 57% above its 5-year average of -74.80%, near the high end of its 5-year range (-399.41%–-19.91%).
As of the fiscal period ended Tuesday, June 30, 2026. 74.11% above its 12-month average of -124.17%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -32.15%.
RETURN ON EQUITY (ROE)
-32.15%
RETURN ON EQUITY (ROE) AVG TTM
-124.17%
RETURN ON EQUITY (ROE) AVG 3Y
-55.91%
RETURN ON EQUITY (ROE) AVG 5Y
-74.80%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+74.11%
CURRENT VS 3Y AVG
+42.50%
CURRENT VS 5Y AVG
+57.02%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.20%
median of 625 covered companies
CURRENT VS SECTOR MEDIAN
+20.03%
vs the sector median at left
Equillium, Inc.
Market Cap
$90.73M
Return on Equity (ROE)
-32.15%
TTM Avg
-124.17%
3Y Avg
-55.91%
5Y Avg
-74.80%
Market Cap
$90.66M
Return on Equity (ROE)
-105.20%
TTM Avg
-53.79%
3Y Avg
-41.98%
5Y Avg
-32.71%
Market Cap
$90.54M
Return on Equity (ROE)
48.20%
TTM Avg
-54.60%
3Y Avg
-54.70%
5Y Avg
-44.17%
Market Cap
$91.83M
Return on Equity (ROE)
-477.87%
TTM Avg
-156.51%
3Y Avg
-83.51%
5Y Avg
-25.98%
Market Cap
$88.48M
Return on Equity (ROE)
2.51%
TTM Avg
-5.84%
3Y Avg
-10.75%
5Y Avg
-7.81%
Market Cap
$93.22M
Return on Equity (ROE)
N/A
TTM Avg
329.82%
3Y Avg
69.21%
5Y Avg
21.28%
Market Cap
$93.63M
Return on Equity (ROE)
-268.09%
TTM Avg
-238.76%
3Y Avg
-155.55%
5Y Avg
-124.74%
Market Cap
$93.80M
Return on Equity (ROE)
-11.85%
TTM Avg
-51.56%
3Y Avg
-105.39%
5Y Avg
-105.39%
Market Cap
$86.90M
Return on Equity (ROE)
45.93%
TTM Avg
16.96%
3Y Avg
-19.36%
5Y Avg
-13.87%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Equillium, Inc. (EQ) | $90.73M | -32.15% | -124.17% | -55.91% | -74.80% |
| PMV Pharmaceuticals, Inc. (PMVP)vs › | $90.66M | -105.20% | -53.79% | -41.98% | -32.71% |
| Rallybio Corporation (RLYB)vs › | $90.54M | 48.20% | -54.60% | -54.70% | -44.17% |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $91.83M | -477.87% | -156.51% | -83.51% | -25.98% |
| ImmuCell Corporation (ICCC)vs › | $88.48M | 2.51% | -5.84% | -10.75% | -7.81% |
| electroCore, Inc. (ECOR)vs › | $93.22M | N/A | 329.82% | 69.21% | 21.28% |
| Biomea Fusion, Inc. (BMEA)vs › | $93.63M | -268.09% | -238.76% | -155.55% | -124.74% |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $93.80M | -11.85% | -51.56% | -105.39% | -105.39% |
| CareCloud, Inc. (CCLD)vs › | $86.90M | 45.93% | 16.96% | -19.36% | -13.87% |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $86.81M | N/A | 1.45% | 25.22% | -14.52% |
ROE
-32.1%
ROA
-30.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -32.15% |
| 2026-03-31 | -32.03% |
| 2025-12-31 | -78.32% |
| 2025-09-30 | -78.92% |
| 2025-06-30 | -399.41% |
| 2025-03-31 | -132.23% |
| 2024-12-31 | -42.32% |
| 2024-09-30 | -19.91% |
| 2024-06-30 | -37.08% |
| 2024-03-31 | -57.50% |
| 2023-12-31 | -59.08% |
| 2023-09-30 | -34.10% |
| 2023-06-30 | -67.33% |
| 2023-03-31 | -98.91% |
| 2022-12-31 | -195.44% |
| 2022-09-30 | -269.25% |
| 2022-06-30 | -179.92% |
| 2022-03-31 | -128.21% |
| 2021-12-31 | -58.72% |
| 2021-09-30 | -49.27% |
| 2021-06-30 | -39.71% |
| 2021-03-31 | -33.70% |
| 2020-12-31 | -42.68% |
| 2020-09-30 | -36.43% |
| 2020-06-30 | -90.01% |
| 2020-03-31 | -75.63% |
| 2019-12-31 | -61.17% |
| 2019-09-30 | -47.03% |
| 2019-06-30 | -40.56% |
| 2019-03-31 | -29.62% |
| 2018-12-31 | -20.41% |
| 2018-06-30 | -74.76% |
